Paper Details

  1. Home
  2. Paper Details

Effects of antiplatelet agents on subacute thrombosis and restenosis after successful coronary stenting: a randomized comparison of ticlopidine and cilostazol.

Author: AdachiHitoshi, HoshizakiHiroshi, KurabayashiMasahiko, OhshimaShigeru, SekiguchiMakoto, TaniguchiKoichi

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This study compared the preventive effects of ticlopidine plus aspirin therapy versus cilostazol plus aspirin therapy on subacute thrombosis (SAT) and restenosis after coronary stenting. The study found that ticlopidine was more effective in preventing SAT, but that cilostazol was more effective in inhibiting neointimal proliferation.
Paper Details　
Original Abstract of the Article :
BACKGROUND: A prospective randomized study compared the preventive effects of ticlopidine plus aspirin therapy versus cilostazol plus aspirin therapy on subacute thrombosis (SAT) and restenosis after coronary stenting. METHODS AND RESULTS: After successful stenting of 327 coronary lesions in 282 co...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1253/circj.68.610

データ提供：米国国立医学図書館（NLM）

Preventing Blood Clots after Stenting: A Comparative Study

This research explores the effectiveness of two antiplatelet medications, ticlopidine and cilostazol, in preventing blood clots and restenosis after coronary stenting. The study involved 282 patients who underwent successful coronary stenting and were randomly assigned to receive either ticlopidine or cilostazol, both combined with aspirin. The findings showed that ticlopidine was more effective in reducing the risk of subacute thrombosis, while cilostazol led to a greater inhibition of neointimal proliferation. However, the study did not confirm a significant difference in the prevention of restenosis between the two medications.

Navigating the Desert of Cardiovascular Disease

This study helps us understand the complex landscape of cardiovascular disease. Just like a desert environment requires careful navigation to avoid the dangers of dehydration and sandstorms, treating cardiovascular disease involves finding the right balance of medications and therapies. This research sheds light on two different approaches to preventing blood clots after stenting, offering valuable insights for physicians and patients.

Minimizing the Risk of Blood Clots

This research highlights the importance of taking antiplatelet medications as prescribed after coronary stenting. These medications help prevent blood clots from forming, which can lead to serious complications. It's like creating a protective barrier in a desert environment to prevent harmful elements from infiltrating your system.

Dr.Camel's Conclusion

This study reveals the complexities of cardiovascular disease and the ongoing search for the best treatments. While both ticlopidine and cilostazol showed promise in reducing the risk of complications after stenting, further research is needed to fully understand their long-term effects and optimize their use. Just like exploring a vast desert, we continue to learn more about cardiovascular health and how to best navigate the challenges it presents.

Date :
  1. Date Completed 2005-04-15
  2. Date Revised 2019-08-19
Further Info :

Pubmed ID

15226623

DOI: Digital Object Identifier

10.1253/circj.68.610

Related Literature

Article Analysis
・Effects of ticlopidine
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.